Cargando…

Family C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications

Alzheimer’s disease (AD), particularly its sporadic or late-onset form (SAD/LOAD), is the most prevalent (96–98% of cases) neurodegenerative dementia in aged people. AD’s neuropathology hallmarks are intrabrain accumulation of amyloid-β peptides (Aβs) and of hyperphosphorylated Tau (p-Tau) proteins,...

Descripción completa

Detalles Bibliográficos
Autores principales: Dal Prà, Ilaria, Armato, Ubaldo, Chiarini, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826475/
https://www.ncbi.nlm.nih.gov/pubmed/31719824
http://dx.doi.org/10.3389/fphar.2019.01282
_version_ 1783465096184332288
author Dal Prà, Ilaria
Armato, Ubaldo
Chiarini, Anna
author_facet Dal Prà, Ilaria
Armato, Ubaldo
Chiarini, Anna
author_sort Dal Prà, Ilaria
collection PubMed
description Alzheimer’s disease (AD), particularly its sporadic or late-onset form (SAD/LOAD), is the most prevalent (96–98% of cases) neurodegenerative dementia in aged people. AD’s neuropathology hallmarks are intrabrain accumulation of amyloid-β peptides (Aβs) and of hyperphosphorylated Tau (p-Tau) proteins, diffuse neuroinflammation, and progressive death of neurons and oligodendrocytes. Mounting evidences suggest that family C G-protein-coupled receptors (GPCRs), which include γ-aminobutyric acid B receptors (GABA(B)Rs), metabotropic glutamate receptors (mGluR1-8), and the calcium-sensing receptor (CaSR), are involved in many neurotransmitter systems that dysfunction in AD. This review updates the available knowledge about the roles of GPCRs, particularly but not exclusively those expressed by brain astrocytes, in SAD/LOAD onset and progression, taking stock of their respective mechanisms of action and of their potential as anti-AD therapeutic targets. In particular, GABA(B)Rs prevent Aβs synthesis and neuronal hyperexcitability and group I mGluRs play important pathogenetic roles in transgenic AD-model animals. Moreover, the specific binding of Aβs to the CaSRs of human cortical astrocytes and neurons cultured in vitro engenders a pathological signaling that crucially promotes the surplus synthesis and release of Aβs and hyperphosphorylated Tau proteins, and also of nitric oxide, vascular endothelial growth factor-A, and proinflammatory agents. Concurrently, Aβs•CaSR signaling hinders the release of soluble (s)APP-α peptide, a neurotrophic agent and GABA(B)R1a agonist. Altogether these effects progressively kill human cortical neurons in vitro and likely also in vivo. Several CaSR’s negative allosteric modulators suppress all the noxious effects elicited by Aβs•CaSR signaling in human cortical astrocytes and neurons thus safeguarding neurons’ viability in vitro and raising hopes about their potential therapeutic benefits in AD patients. Further basic and clinical investigations on these hot topics are needed taking always heed that activation of the several brain family C GPCRs may elicit divergent upshots according to the models studied.
format Online
Article
Text
id pubmed-6826475
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68264752019-11-12 Family C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications Dal Prà, Ilaria Armato, Ubaldo Chiarini, Anna Front Pharmacol Pharmacology Alzheimer’s disease (AD), particularly its sporadic or late-onset form (SAD/LOAD), is the most prevalent (96–98% of cases) neurodegenerative dementia in aged people. AD’s neuropathology hallmarks are intrabrain accumulation of amyloid-β peptides (Aβs) and of hyperphosphorylated Tau (p-Tau) proteins, diffuse neuroinflammation, and progressive death of neurons and oligodendrocytes. Mounting evidences suggest that family C G-protein-coupled receptors (GPCRs), which include γ-aminobutyric acid B receptors (GABA(B)Rs), metabotropic glutamate receptors (mGluR1-8), and the calcium-sensing receptor (CaSR), are involved in many neurotransmitter systems that dysfunction in AD. This review updates the available knowledge about the roles of GPCRs, particularly but not exclusively those expressed by brain astrocytes, in SAD/LOAD onset and progression, taking stock of their respective mechanisms of action and of their potential as anti-AD therapeutic targets. In particular, GABA(B)Rs prevent Aβs synthesis and neuronal hyperexcitability and group I mGluRs play important pathogenetic roles in transgenic AD-model animals. Moreover, the specific binding of Aβs to the CaSRs of human cortical astrocytes and neurons cultured in vitro engenders a pathological signaling that crucially promotes the surplus synthesis and release of Aβs and hyperphosphorylated Tau proteins, and also of nitric oxide, vascular endothelial growth factor-A, and proinflammatory agents. Concurrently, Aβs•CaSR signaling hinders the release of soluble (s)APP-α peptide, a neurotrophic agent and GABA(B)R1a agonist. Altogether these effects progressively kill human cortical neurons in vitro and likely also in vivo. Several CaSR’s negative allosteric modulators suppress all the noxious effects elicited by Aβs•CaSR signaling in human cortical astrocytes and neurons thus safeguarding neurons’ viability in vitro and raising hopes about their potential therapeutic benefits in AD patients. Further basic and clinical investigations on these hot topics are needed taking always heed that activation of the several brain family C GPCRs may elicit divergent upshots according to the models studied. Frontiers Media S.A. 2019-10-28 /pmc/articles/PMC6826475/ /pubmed/31719824 http://dx.doi.org/10.3389/fphar.2019.01282 Text en Copyright © 2019 Dal Prà, Armato and Chiarini http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Dal Prà, Ilaria
Armato, Ubaldo
Chiarini, Anna
Family C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications
title Family C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications
title_full Family C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications
title_fullStr Family C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications
title_full_unstemmed Family C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications
title_short Family C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications
title_sort family c g-protein-coupled receptors in alzheimer’s disease and therapeutic implications
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826475/
https://www.ncbi.nlm.nih.gov/pubmed/31719824
http://dx.doi.org/10.3389/fphar.2019.01282
work_keys_str_mv AT dalprailaria familycgproteincoupledreceptorsinalzheimersdiseaseandtherapeuticimplications
AT armatoubaldo familycgproteincoupledreceptorsinalzheimersdiseaseandtherapeuticimplications
AT chiarinianna familycgproteincoupledreceptorsinalzheimersdiseaseandtherapeuticimplications